News and Events

Developing the
‘on’ switch for

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.

Oncolytic immunotherapy is expected to enhance the effectiveness of immune checkpoint blockade and become the second cornerstone of immune-oncology approaches, moving beyond incremental improvement in cancer treatment to help more patients overcome their disease.

Replimune co-founders Philip Astley-Sparke, CEO & Robert Coffin, President & Chief of R&D, detail the potential of oncolytic immunotherapy (OI) & our belief that OI is poised to change the paradigm in cancer treatment. Read more

Our Immulytic™ Platform

The “On-Switch” in Immuno-Oncology

Novel Therapeutics

Rapidly Advancing Clinical Programs

Experienced Team

Pioneers in Oncolytic Immunotherapy